Clinical Trials Sponsored by Foresee Pharmaceuticals

Total 21313 results

Forest Laboratories

Completed

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

Urinary Tract Infections

Russian Federation, Bulgaria, Poland, Germany, United States, Lebanon, Turkey
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Hypertension

United States
Forest Laboratories

Withdrawn

Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia (CABP)
Forest Laboratories

Completed

Safety Study of F2695 SR in Major Depressive Disorder (LVM-MD-04)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

Stage 2 Diastolic Hypertension

United States, Puerto Rico
Forest Laboratories

Completed

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Forest Laboratories

Completed

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

Dyspepsia

United States
Forest Laboratories

Completed

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Forest Laboratories

Completed

Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.

Atrial Fibrillation

Germany, France, Belgium, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain
Forest Laboratories

Completed

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Atrial Fibrillation

United States, Canada
Forest Laboratories

Completed

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Hypertension | Type 2 Diabetes Mellitus

United States, Puerto Rico
Forest Laboratories

Completed

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Escitalopram in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, New Zealand, South Africa
Forest Laboratories

Completed

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Hypertension

United States
Forest Laboratories

Completed

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, Canada
Forest Laboratories

Completed

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (VLZ-MD-05)

Generalized Anxiety Disorder

United States
Forest Laboratories

Completed

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Diafert for Embryo Selection and Fertility Improvement (DESTINy) (DESTINy)

Infertility

Hungary
Forest Laboratories

Terminated

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Neoplasms | Febrile Neutropenia

United States
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency | Pancreatectomy

Canada, United States, Poland, Slovakia
Forest Laboratories

Completed

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Bacterial Infection

United States
Forest Laboratories

Completed

Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)

Nausea

Canada
Forest Laboratories

Completed

Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

Nausea

Canada
Forest Laboratories

Completed

Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
Forest Laboratories

Completed

Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

Congestive Heart Failure

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

Infections | Pneumonia

United States, Ukraine, Argentina, Georgia
Forest Laboratories

Completed

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

Schizophrenia

United States
Forest Laboratories

Completed

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine, Australia, Canada, France, Singapore
Forest Laboratories

Completed

Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

Germany, Poland
Forest Laboratories

Completed

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Study of Oglemilast for the Prevention of Asthma.

Exercise-Induced Asthma

United States
Forest Laboratories

Completed

Study of Oglemilast for the Treatment of Asthma

Asthma

United States
Forest Laboratories

Completed

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

Schizophrenia

United States
Forest Laboratories

Completed

Study of Escitalopram in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

Bipolar Disorder

United States
Forest Laboratories

Completed

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

Arrhythmia

United States, Canada, Germany, Belgium, France, Italy, Netherlands, Poland, Spain
Forest Laboratories

Completed

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

Hypertension

United States, Puerto Rico

3

Subscribe